Boehringer Ingelheim Corporation
Boehringer Ingelheim Corporation, a leading global pharmaceutical company, is headquartered in the United States and operates extensively across Europe, Asia, and other regions. Founded in 1885, the company has established itself as a key player in the pharmaceutical and animal health industries, focusing on innovative research and development. Boehringer Ingelheim is renowned for its core products, which include prescription medications, vaccines, and animal health solutions. Their commitment to advancing healthcare through unique therapeutic approaches sets them apart in a competitive market. With a strong emphasis on human and veterinary medicine, the company has achieved notable milestones, including significant advancements in respiratory and cardiovascular treatments. As a prominent entity in the pharmaceutical landscape, Boehringer Ingelheim continues to enhance its market position through a dedication to innovation and sustainability, making a lasting impact on global health.
DitchCarbon Score
How does Boehringer Ingelheim Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boehringer Ingelheim Corporation's score of 13 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Boehringer Ingelheim Corporation's reported carbon emissions
Boehringer Ingelheim Corporation, headquartered in the US, currently does not provide specific carbon emissions data or reduction targets. Without available figures on their emissions, it is unclear how they are addressing their carbon footprint. However, the company is likely to be engaged in industry-standard climate commitments, which typically include initiatives aimed at reducing greenhouse gas emissions across various scopes (Scope 1, 2, and 3). In the absence of detailed emissions data or specific reduction initiatives, it is essential to note that many corporations in the pharmaceutical sector are increasingly focusing on sustainability and climate action. This often involves setting science-based targets and committing to net-zero emissions in the long term. As Boehringer Ingelheim continues to navigate its environmental responsibilities, stakeholders may look for future disclosures that outline their climate strategies and progress in reducing their carbon emissions.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boehringer Ingelheim Corporation is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
